"Our acquisition of PCT is proving to be not only accretive but also generating a cost savings for NeoStem while accelerating our mission to be a global leader in cell therapy," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "We are thrilled that such high caliber industry veterans have chosen to join PCT to assist us with our client-focused development and manufacturing and our growing portfolio of cellular therapeutic candidates." "Dr. Fong and Dr. O'Neill lend their considerable expertise to PCT's clients and to NeoStem's preclinical and clinical development programs," said Dr Robert Preti, President and Chief Scientific Officer of PCT. "These key additions will add to our reputation in the industry as the "go-to" company to enable effective development and manufacturing of cellular therapeutics for our expanding client base."
About NeoStem, Inc.NeoStem is a leader in the development and manufacturing of cell therapies. The Company's strategic combination of revenues with manufacturing through its subsidiary, Progenitor Cell Therapy, LLC and global reach has positioned the company for breakthroughs in the cell therapy industry. The acquisition of Amorcyte, Inc., closed on October 17, 2011, positions NeoStem to achieve its mission of capturing the paradigm shift to cell therapy. NeoStem is also pursuing a T-cell therapeutic with potential in a range of auto-immune conditions and development of its VSEL™ Technology platform. For more information on NeoStem, please visit www.neostem.com.
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved